EGFR and neoplasm: The limitations of our study include its retrospective nature, which resulted in missing data that have been previously associated with PFS, such as corrected tumor mutational burden [5,6,52], combinations of STK11, KEAP, and EGFR mutations [6], human leukocyte antigens [5], or tertiary lymphoid structure [7].